Feb 1 (Reuters) - Getinge AB GETIb.ST :
* PROPOSES DIVIDEND OF SEK 4.40 PER SHARE VERSUS IBES
ESTIMATE SEK
4.1 PER SHARE
* OUTLOOK 2024: NET SALES FOR 2024 ARE EXPECTED TO INCREASE
BY
2–5% ORGANICALLY
* SALES OF HARDWARE IN CARDIAC ASSIST CONTINUED TO RECOVER,
WHICH
HAD SUBSTANTIALLY POSITIVE EFFECT ON SALES FOR ACUTE CARE
THERAPIES
* SALES INCREASED IN LIFE SCIENCE WHERE SLIGHT RECOVERY WAS
NOTED
IN BIOPHARMA SEGMENT
* SURGICAL WORKFLOWS REPORTED STRONG QUARTER FOR ALL PRODUCT
CATEGORIES, WITH ORGANIC GROWTH OF 15.6%
* ORDER INTAKE INCREASED BY 4.1% IN THE QUARTER, DRIVEN BY
ACQUISITIONS AND CURRENCY
* DESPITE WEAKER ORDER INTAKE, EXISTING ORDER BOOK AND
DIALOGUE
WITH CUSTOMERS LEAD US TO EXPECT ORGANIC SALES GROWTH OF 2-5%
FOR 2024
* TWO ACQUISITIONS COMPLETED IN Q4 2023 ARE EXPECTED TO
CONTRIBUTE
WITH 3-5% SALES GROWTH IN 2024
* ADJUSTED EBITA MARGIN LOWER THAN 2022, MAINLY DUE TO THE
QUALITY
COSTS FOR QUALITY IMPROVEMENT WORK IN ACUTE CARE THERAPIES
* QUALITY COSTS EXPECTED TO CONTINUE TO AFFECT INTO 2024,
UNTIL WE
HAVE RECTIFIED THE CURRENT DEFICIENCIES
* MARGIN WAS NEGATIVELY IMPACTED BY GENERALLY UNFAVORABLE
GEOGRAPHIC AND PRODUCT-RELATED MIX AND HIGHER COSTS FOR INPUT
GOODS AND EMPLOYEES
* LIFE SCIENCE INCREASED ORDER INTAKE IN ALL PRODUCT
CATEGORIES
EXCEPT FOR BIO-PROCESSING, TREND IN THE US WAS STRONG WHILE
ORDER INTAKE IN CHINA REMAINED WEAK
Source text for Eikon: ID:nWkr3tNylb
Further company coverage: GETIb.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))